Literature DB >> 31704813

Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells.

Kazuki Okubo1, Makoto Isono1, Takako Asano1, Akinori Sato2.   

Abstract

BACKGROUND/AIM: Induction of endoplasmic reticulum (ER) stress is a novel approach to cancer treatment. This study investigated the ability of the clinically feasible combination of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir to induce ER stress killing urological cancer cells.
MATERIALS AND METHODS: Renal cancer cells (769-P, 786-O) and bladder cancer cells (UMUC-3, T-24) were used to investigate the ability of the combination to induce ER stress and its mechanism of action.
RESULTS: The combination inhibited the growth of both renal and bladder cancer cells synergistically by inducing ER stress. The combination-induced ER stress increased the expression of AMP-activated protein kinase and suppressed the mammalian target of rapamycin pathway. It also increased the expression of a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor and thereby sensitized the cancer cells to TRAIL.
CONCLUSION: The combination of lopinavir and ritonavir acts against urological cancer cells by inducing ER stress synergistically. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  AMP-activated protein kinase; Lopinavir; bladder cancer; endoplasmic reticulum stress; renal cancer; ritonavir; tumor necrosis factor-related apoptosis-inducing ligand

Mesh:

Substances:

Year:  2019        PMID: 31704813     DOI: 10.21873/anticanres.13793

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs.

Authors:  Giovanni Barillari
Journal:  Front Oncol       Date:  2020-05-21       Impact factor: 6.244

2.  Acetylsalicylic acid and salicylic acid present anticancer properties against melanoma by promoting nitric oxide-dependent endoplasmic reticulum stress and apoptosis.

Authors:  Priscila Ausina; Jessica R Branco; Thainá M Demaria; Amanda M Esteves; João Gabriel B Leandro; Alan C Ochioni; Ana Paula M Mendonça; Fernando L Palhano; Marcus F Oliveira; Wassim Abou-Kheir; Mauro Sola-Penna; Patricia Zancan
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

3.  An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer.

Authors:  Facai Zhang; Dechao Feng; Xiaoming Wang; Yiwei Gu; Zhiyong Shen; Yubo Yang; Jiahao Wang; Quliang Zhong; Dengxiong Li; Huan Hu; Ping Han
Journal:  Front Mol Biosci       Date:  2021-12-23

4.  The (Still Unknown) Hypothetical Protective Role of COVID-19 Therapy in Bladder Cancer.

Authors:  Luca Di Gianfrancesco
Journal:  J Clin Med       Date:  2021-11-23       Impact factor: 4.241

5.  Inhibitory Mechanism of Combined Hydroxychavicol With Epigallocatechin-3-Gallate Against Glioma Cancer Cell Lines: A Transcriptomic Analysis.

Authors:  Amirah Abdul Rahman; Wan Zurinah Wan Ngah; Rahman Jamal; Suzana Makpol; Roslan Harun; Norfilza Mokhtar
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

Review 6.  Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.

Authors:  Shafina Siddiqui; Ankita Jaywant Deshmukh; Priyanka Mudaliar; Apoorva Jagannath Nalawade; Deepak Iyer; Jyotirmoi Aich
Journal:  J Egypt Natl Canc Inst       Date:  2022-08-08

7.  Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line.

Authors:  Allison B Coffin; Emily Dale; Emilee Doppenberg; Forrest Fearington; Tamasen Hayward; Jordan Hill; Olivia Molano
Journal:  Front Cell Neurosci       Date:  2022-08-24       Impact factor: 6.147

Review 8.  Drug repurposing against COVID-19: focus on anticancer agents.

Authors:  Gennaro Ciliberto; Rita Mancini; Marco G Paggi
Journal:  J Exp Clin Cancer Res       Date:  2020-05-12

Review 9.  Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives.

Authors:  Ebrahim Rahmani Moghadam; Hui Li Ang; Sholeh Etehad Asnaf; Amirhossein Zabolian; Hossein Saleki; Mohammad Yavari; Hossein Esmaeili; Ali Zarrabi; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-09-27

Review 10.  Coronavirus COVID- 19: A critical review of its history, pathogenesis, transmission, diagnosis and treatment.

Authors:  Mohd Sharjeel Sofi; Aadil Hamid; Sami Ullah Bhat
Journal:  Biosaf Health       Date:  2020-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.